Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Micromet first quarter total revenues decrease to $5.5 million

Micromet first quarter total revenues decrease to $5.5 million

EpiCept first quarter net loss decreases to $2.5 million

EpiCept first quarter net loss decreases to $2.5 million

MHA's annual awards recognize outstanding health care leaders, innovative programs

MHA's annual awards recognize outstanding health care leaders, innovative programs

Mary Ann Liebert publishes new journal on cancer care for adolescent and young adult patients

Mary Ann Liebert publishes new journal on cancer care for adolescent and young adult patients

Karmanos Cancer Institute raises funds for patient care and research

Karmanos Cancer Institute raises funds for patient care and research

Brain cancer research needs $50 billion to find cure

Brain cancer research needs $50 billion to find cure

University of California, Irvine Medical Center introduce Journal of Adolescent and Young Adult Oncology

University of California, Irvine Medical Center introduce Journal of Adolescent and Young Adult Oncology

CytRx reports $6.3 million net loss for first quarter 2011

CytRx reports $6.3 million net loss for first quarter 2011

Genome epigenetic analysis reveals new ways to detect and treat breast cancer

Genome epigenetic analysis reveals new ways to detect and treat breast cancer

Study: XMRV retrovirus is not present in chronic fatigue syndrome patients

Study: XMRV retrovirus is not present in chronic fatigue syndrome patients

Three hundred neurosurgeons to participate in Central Park softball tournament

Three hundred neurosurgeons to participate in Central Park softball tournament

MorphoSys reaches second clinical milestone with OncoMed Pharmaceuticals

MorphoSys reaches second clinical milestone with OncoMed Pharmaceuticals

FDA approves orphan drug designation for Cytrx’s INNO-206 to treat pancreatic cancer

FDA approves orphan drug designation for Cytrx’s INNO-206 to treat pancreatic cancer

Tarix begins patient enrollment for TXA127 Phase 1 study in DCBT

Tarix begins patient enrollment for TXA127 Phase 1 study in DCBT

CSI's cancer cytogenetic testing receives COG approval

CSI's cancer cytogenetic testing receives COG approval

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

ARIAD executes three exclusive out-license agreements for ARGENT cell-signaling regulation technology

ARIAD executes three exclusive out-license agreements for ARGENT cell-signaling regulation technology

Clontech releases iDimerize inducible dimerization systems

Clontech releases iDimerize inducible dimerization systems

Sequencing the genomes of cancer patients help doctors decide the best course of treatment

Sequencing the genomes of cancer patients help doctors decide the best course of treatment

Whole-genome sequencing could soon improve cancer survival rates

Whole-genome sequencing could soon improve cancer survival rates

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.